Abstract
The majority of cases of ornithine transcarbamylase deficiency are due to novel mutations making it impossible to develop common methods for genetic analysis. However, identification of causative mutations has important implications for diagnosis (particularly prenatal diagnosis), prediction of likely course and outcome and the eventual possibility of gene therapy. As part of a continuing study of ornithine transcarbamylase deficiency, we now report an additional thirty novel mutations in the ornithine transcarbamylase gene, together with a brief summary of their clinical presentations.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Tuchman M (1993) Mutations and polymorphisms in the human ornithine transcarbamylase gene. Hum Mutat 2: 174–178.
Tuchman M, Plante RJ (1995) Mutations and polymorphisms in the human ornithine transcarbamylase gene: mutation update addendum. Hum Mutat 5: 293–295.
Tuchman M, Morizono H, Reish O, Yuan X, Allewell NM (1995) The molecular basis of ornithine transcarbamylase deficiency: modeling the human enzyme and the effects of mutations. J Med Genet 32: 680–688.
Tuchman M, Plante RJ, Garcia-Perez MA, Rubio V (1996) Relative frequency of mutations causing ornithine transcarbamylase deficiency in 78 families. Hum Genet 97: 274–276.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tuchman, M., Morizono, H., Rajagopal, B.S. et al. Identification of ‘private’ mutations in patients with ornithine transcarbamylase deficiency. J Inherit Metab Dis 20, 525–527 (1997). https://doi.org/10.1023/A:1005301513465
Issue Date:
DOI: https://doi.org/10.1023/A:1005301513465